X
[{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Kerry Murphy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Axonis Therapeutics"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Distributed Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Distributed Bio Partners With Mediar Therapeutics, Inc.","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Mediar Therapeutics"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Aravive","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics and Aravive Collaborate to Develop Novel Antibodies Targeting Cancer and Fibrosis Using the WuXiBody\u2122 Platform","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"WuXi Biologics"},{"orgOrder":0,"company":"UMass Dartmouth","sponsor":"CaaMTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CaaMTech Expands Successful Next-Gen Drug Research Collaboration with UMass Dartmouth","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"UMass Dartmouth"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company
Sponsor
Country
Product Type
News Type
Details:
The renewal and expansion of this collaboration recognizes the success of Associate Professor of Chemistry & Biochemistry Dr. David R. Manke and his associated team of researchers in the synthesis and crystallography of novel tryptamines.
Lead Product(s):
Tryptamine
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
CaaMTech
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration
December 09, 2020
Details:
Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.
Lead Product(s):
Neutralizing antibodies
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Distributed Bio
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
June 03, 2020
Details:
The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.
Lead Product(s):
KCC2
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Kerry Murphy
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Financing
May 28, 2020
Details:
Collaboration grants Aravive the right to use the proprietary WuXiBody™ platform to develop high-affinity bispecific antibodies for a target implicated in cancer and fibrosis.
Lead Product(s):
Bispecific antibodies
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Aravive
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
April 30, 2020